GB0103877D0 - Novel Drug Delivery system - Google Patents

Novel Drug Delivery system

Info

Publication number
GB0103877D0
GB0103877D0 GBGB0103877.7A GB0103877A GB0103877D0 GB 0103877 D0 GB0103877 D0 GB 0103877D0 GB 0103877 A GB0103877 A GB 0103877A GB 0103877 D0 GB0103877 D0 GB 0103877D0
Authority
GB
United Kingdom
Prior art keywords
delivery system
drug delivery
novel drug
novel
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0103877.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB0103877.7A priority Critical patent/GB0103877D0/en
Publication of GB0103877D0 publication Critical patent/GB0103877D0/en
Priority to JP2002565625A priority patent/JP2004521911A/ja
Priority to US10/468,112 priority patent/US20040110678A1/en
Priority to PCT/GB2002/000680 priority patent/WO2002066067A2/en
Priority to CA002476397A priority patent/CA2476397A1/en
Priority to AU2002229994A priority patent/AU2002229994A1/en
Priority to EP02711103A priority patent/EP1359941A2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GBGB0103877.7A 2001-02-16 2001-02-16 Novel Drug Delivery system Ceased GB0103877D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0103877.7A GB0103877D0 (en) 2001-02-16 2001-02-16 Novel Drug Delivery system
JP2002565625A JP2004521911A (ja) 2001-02-16 2002-02-15 投薬方式
US10/468,112 US20040110678A1 (en) 2001-02-16 2002-02-15 Novel drug delivery system
PCT/GB2002/000680 WO2002066067A2 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides
CA002476397A CA2476397A1 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides
AU2002229994A AU2002229994A1 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides
EP02711103A EP1359941A2 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103877.7A GB0103877D0 (en) 2001-02-16 2001-02-16 Novel Drug Delivery system

Publications (1)

Publication Number Publication Date
GB0103877D0 true GB0103877D0 (en) 2001-04-04

Family

ID=9908913

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0103877.7A Ceased GB0103877D0 (en) 2001-02-16 2001-02-16 Novel Drug Delivery system

Country Status (7)

Country Link
US (1) US20040110678A1 (enExample)
EP (1) EP1359941A2 (enExample)
JP (1) JP2004521911A (enExample)
AU (1) AU2002229994A1 (enExample)
CA (1) CA2476397A1 (enExample)
GB (1) GB0103877D0 (enExample)
WO (1) WO2002066067A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
AT509192B1 (de) * 2010-06-24 2011-07-15 Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems Sorptionsmittel für endotoxine
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
FR3002452B1 (fr) * 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
WO2015136311A1 (en) * 2014-03-13 2015-09-17 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof
US10071141B2 (en) * 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
CA2267179A1 (en) * 1996-09-26 1998-04-02 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
WO2000033884A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugates of lipids and antimicrobial or antineoplastic drugs
CA2375502A1 (en) * 1999-06-23 2000-12-28 The Wistar Institute Of Anatomy & Biology Novel pyrrhocoricin-derived peptides, and methods of use thereof
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel

Also Published As

Publication number Publication date
CA2476397A1 (en) 2002-08-29
AU2002229994A1 (en) 2002-09-04
JP2004521911A (ja) 2004-07-22
EP1359941A2 (en) 2003-11-12
WO2002066067A3 (en) 2003-02-13
WO2002066067A2 (en) 2002-08-29
US20040110678A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
HUP0401438A3 (en) Drug delivery system
GB2421689B (en) Drug delivery system
AU2002244142A1 (en) Integrated medication delivery system
IL159875A0 (en) Zero order controlled drug delivery system
GB0123633D0 (en) Stent delivery system
PL1631255T3 (pl) System dostarczania leków
PL376169A1 (en) Drug delivery system
AU2002352344A8 (en) Medicament delivery assembly
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
EP1450876A4 (en) INTEGRATED TRANSDERMAL DRUG DELIVERY SYSTEM
AUPR573001A0 (en) Lymphatic drug delivery system
GB0103877D0 (en) Novel Drug Delivery system
GB0100115D0 (en) Delivery systems
GB0029843D0 (en) Drug delivery system
GB9930160D0 (en) Drug delivery
AU2002210580A1 (en) Drug delivery system
GB0102725D0 (en) Medical delivery system
GB0115136D0 (en) Drug delivery system
GB0112326D0 (en) Drug delivery system
GB0113857D0 (en) Delivery system
GB0118366D0 (en) Multiple-therapy drug delivery
GB0102667D0 (en) Drug delivery
HK1065475A (en) Drug delivery system
AU2002228323A1 (en) Spaced drug delivery system
GB0105958D0 (en) Delivery system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)